(Q83014172)

English

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation

scientific article published on 16 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Francesco Merli

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Pellegrino Musto

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

object named as

Giuseppe Rossi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Andrea Ferrario

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Alessandro Pulsoni

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Barbara Olivero

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Alessandra Tedeschi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Luigi Rigacci

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Caterina Stelitano

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Maria Goldaniga

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Donato Mannina

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Francesca Rossi

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Enrica Gamba

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

16 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

3954-3961

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Epidemiology, pathology and treatment of non-follicular indolent lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

How I treat Waldenström macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Traditional treatment approaches in B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-based treatments in Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26708

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26708

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22179904%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83014172&oldid=2084033925"